DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines
Language English Country Greece Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
25739012
PubMed Central
PMC4391593
DOI
10.3892/or.2015.3819
Knihovny.cz E-resources
- MeSH
- Folic Acid Antagonists administration & dosage MeSH
- Drug Resistance, Neoplasm genetics MeSH
- Tetrahydrofolate Dehydrogenase metabolism MeSH
- Humans MeSH
- Medulloblastoma * enzymology genetics MeSH
- Methotrexate administration & dosage MeSH
- Cell Line, Tumor MeSH
- Bone Neoplasms * enzymology genetics MeSH
- Cerebellar Neoplasms * enzymology genetics MeSH
- Osteosarcoma * enzymology genetics MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Cell Proliferation drug effects MeSH
- Flow Cytometry MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Folic Acid Antagonists MeSH
- Tetrahydrofolate Dehydrogenase MeSH
- Methotrexate MeSH
Although methotrexate (MTX) is the most well-known antifolate included in many standard therapeutic regimens, substantial toxicity limits its wider use, particularly in pediatric oncology. Our study focused on a detailed analysis of MTX effects in cell lines derived from two types of pediatric solid tumors: medulloblastoma and osteosarcoma. The main aim of this study was to analyze the effects of treatment with MTX at concentrations comparable to MTX plasma levels in patients treated with high-dose or low-dose MTX. The results showed that treatment with MTX significantly decreased proliferation activity, inhibited the cell cycle at S-phase and induced apoptosis in Daoy and Saos-2 reference cell lines, which were found to be MTX-sensitive. Furthermore, no difference in these effects was observed following treatment with various doses of MTX ranging from 1 to 40 µM. These findings suggest the possibility of achieving the same outcome with the application of low-dose MTX, an extremely important result, particularly for clinical practice. Another important aspect of treatment with high-dose MTX in clinical practice is the administration of leucovorin (LV) as an antidote to reduce MTX toxicity in normal cells. For this reason, the combined application of MTX and LV was also included in our experiments; however, this application of MTX together with LV did not elicit any detectable effect. The expression analysis of genes involved in the mechanisms of resistance to MTX was a final component of our study, and the results helped us to elucidate the mechanisms of the various responses to MTX among the cell lines included in our study.
Department of Experimental Biology School of Science Masaryk University Brno Czech Republic
Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czech Republic
See more in PubMed
Takimoto CH. New Antifolates: Pharmacology and Clinical Applications. Oncologist. 1996;1:68–81. PubMed
Neradil J, Pavlasova G, Veselska R. New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol. 2012;25:2S87–2S92. PubMed
Sterba J, Valík D, Bajciová V, Kadlecová V, Gregorová V, Mendelová D. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma. 2005;52:456–463. PubMed
Sterba J, Dusek L, Demlova R, Valik D. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: ‘folate overrescue’ concept revisited. Clin Chem. 2006;52:692–700. doi: 10.1373/clinchem.2005.061150. PubMed DOI
Wang JJ, Li GJ. Relationship between RFC gene expression and intracellular drug concentration in methotrexate-resistant osteosarcoma cells. Genet Mol Res. 2014;13:5313–5321. doi: 10.4238/2014.July.24.10. PubMed DOI
Fotoohi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma. 2008;49:410–426. doi: 10.1080/10428190701824569. PubMed DOI
Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007;26:153–181. doi: 10.1007/s10555-007-9049-z. PubMed DOI
Veselska R, Neradil J, Nekulova M, Dobrucka L, Vojtesek B, Sterba J, Zitterbart K. Intracellular distribution of the ΔNp73 protein isoform in medulloblastoma cells: a study with newly generated rabbit polyclonal antibodies. Histol Histopathol. 2013;28:913–924. PubMed
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–675. doi: 10.1038/nmeth.2089. PubMed DOI PMC
Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73:106–114. doi: 10.1111/j.1365-2125.2011.04054.x. PubMed DOI PMC
Rahiem Ahmed YAA, Hasan Y. Prevention and management of high dose methotrexate toxicity. J Cancer Sci Ther. 2013;5:106–112.
Cohen IJ1, Wolff JE. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer. 2014;61:7–10. doi: 10.1002/pbc.24770. PubMed DOI
Najim N, Podmore ID, McGown A, Estlin EJ. Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. Anticancer Res. 2009;29:3103–3108. PubMed
Assaraf YG, Ifergan I, Kadry WN, Pinter RY. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets. J Theor Biol. 2006;240:637–647. doi: 10.1016/j.jtbi.2005.11.001. PubMed DOI
Bastian L, Einsiedel HG, Henze G, Seeger K, Shalapour S. The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells. Leukemia. 2011;25:359–361. doi: 10.1038/leu.2010.259. PubMed DOI
Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007;26:183–201. doi: 10.1007/s10555-007-9050-6. PubMed DOI
Yoon SA, Choi JR, Kim JO, Shin JY, Zhang X, Kang JH. Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity. Cancer Res Treat. 2010;42:163–171. doi: 10.4143/crt.2010.42.3.163. PubMed DOI PMC
Nazki FH, Sameer AS, Ganaie BA. Folate: metabolism, genes, polymorphisms and the associated diseases. Gene. 2014;533:11–20. doi: 10.1016/j.gene.2013.09.063. PubMed DOI
Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta. 2010;1805:141–152. PubMed PMC
Rots MG, Willey JC, Jansen G, van Zantwijk CH, Noordhuis P, DeMuth JP, Kuiper E, Veerman AJ, Pieters R, Peters GJ. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia. 2000;14:2166–2175. doi: 10.1038/sj.leu.2401943. PubMed DOI
Nilubol N, Zhang L, Shen M, Zhang YQ, He M, Austin CP, Kebebew E. Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. J Transl Med. 2012;10:198. doi: 10.1186/1479-5876-10-198. PubMed DOI PMC
Capelôa T, Caramelo F, Fontes-Ribeiro C, Gomes C, Silva AP. Role of methamphetamine on glioblastoma cytotoxicity induced by Doxorubicin and methotrexate. Neurotox Res. 2014;26:216–227. doi: 10.1007/s12640-014-9464-1. PubMed DOI
Yan KH, Lee LM, Hsieh MC, Yan MD, Yao CJ, Chang PY, Chen TL, Chang HY, Cheng AL, Lai GM, Chuang SE. Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells. Oncol Rep. 2013;30:1497–1505. PubMed
Hattangadi DK, DeMasters GA, Walker TD, Jones KR, Di X, Newsham IF, Gewirtz DA. Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell. Biochem Pharmacol. 2004;68:1699–1708. doi: 10.1016/j.bcp.2004.06.033. PubMed DOI
Hellwinkel OJ, Müller J, Pollmann A, Kabisch H. Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes. J Gene Med. 2005;7:407–419. doi: 10.1002/jgm.684. PubMed DOI
Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, Resnick MA. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res. 2010;8:701–716. doi: 10.1158/1541-7786.MCR-09-0442. PubMed DOI PMC
Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol. 2012;14:859–869. doi: 10.1093/neuonc/nos115. PubMed DOI PMC
Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, Gross TG, Abromowitch M. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol. 2013;162:792–801. doi: 10.1111/bjh.12460. PubMed DOI
